Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Journal of Cancer·2026
Same author

Seronegative Paraneoplastic Limbic Encephalitis in Non-Small Cell Lung Cancer: A Case of Neuropsychiatric Symptoms Resolving After Resection.

Annals of thoracic surgery short reports·2026
Same author

FcRn function alone cannot account for elevated IgG clearance in the Lewis lung carcinoma model of cancer cachexia.

International immunopharmacology·2026
Same author

Fc gamma receptor binding modulates IgG clearance in cancer cachexia.

Frontiers in immunology·2026
Same author

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Cancer immunology, immunotherapy : CII·2026

Related Experiment Video

Updated: Dec 23, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.7K

Biomarkers for Immunotherapy.

Jean G Bustamante-Alvarez1, Dwight H Owen1

  • 1Division of Medical Oncology, Department of Internal Medicine, Ohio State University Wexner Medical Center, 320 West 10th Avenue, A450B Starling Loving Hall, Columbus, OH 43210, USA.

Thoracic Surgery Clinics
|April 25, 2020
PubMed
Summary

Biomarkers are crucial for predicting patient response to immune checkpoint inhibitor (ICI) therapy in solid tumors like non-small cell lung cancer. Understanding tumor genomics and the tumor microenvironment aids in selecting patients for immunotherapy.

Keywords:
BiomarkersCheckpoint inhibitorImmunotherapyNon–small cell lung cancer (NSCLC)PD-L1

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K

Related Experiment Videos

Last Updated: Dec 23, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Immune checkpoint inhibitors (ICIs) offer durable responses in several solid tumors, including non-small cell lung cancer, outperforming chemotherapy in select patients.
  • Predictive biomarkers are essential for optimizing patient selection and treatment strategies for ICI therapy.
  • Tumor genomics and the tumor microenvironment significantly influence response to immunotherapy.

Purpose of the Study:

  • To review existing data on biomarkers for predicting response to immune checkpoint inhibitor therapy.
  • To explore novel biomarkers currently under investigation for optimizing patient selection.
  • To enhance the efficacy of immunotherapy by improving patient stratification.

Main Methods:

  • Literature review of studies investigating biomarkers for immune checkpoint inhibitor response.
  • Analysis of data linking tumor genomics, immune system interactions, and tumor microenvironment to treatment outcomes.
  • Synthesis of evidence supporting the use of established and emerging biomarkers.

Main Results:

  • Biomarkers related to tumor genomics and the immune microenvironment show promise in predicting ICI response.
  • Established biomarkers aid in selecting patients who are likely to benefit from immunotherapy.
  • Ongoing research is identifying new biomarkers for broader application.

Conclusions:

  • Biomarker-driven patient selection is critical for maximizing the benefits of immune checkpoint inhibitors.
  • Further research into tumor genomics and the tumor microenvironment will refine predictive models.
  • Optimizing patient selection through biomarkers will improve outcomes in non-small cell lung cancer and other solid tumors.